K

Keros Therapeutics Tech Stack

TGF-β targeted therapeutics in preclinical and early-stage development

Biotechnology Research Lexington, Massachusetts 51–200 employees Founded 2016 Public Company

Keros is a biotech company focused on therapeutics targeting transforming growth factor-beta signaling pathways, currently in preclinical and early clinical stages. The hiring profile is heavily skewed toward research (16 of 30 open roles) and dominated by interns (16 of 30), indicating active scaling of hands-on lab capacity rather than leadership expansion. The pain-point cluster around clinical trial operations, data governance, and GLP/GCP compliance signals a company navigating the transition from discovery into regulated preclinical work.

Tech Stack 11 technologies

Core StackDocuSign Microsoft Office qPCR GraphPad Prism SDS-PAGE HPLC Excel PowerPoint Word Veeva QualityDocs SPSS

What Keros Therapeutics Is Building

◆Challenges

Risk management challenges in clinical trials
Operational inefficiencies in clinical trials
Technical issues across informatics systems
Data governance challenges
Performance bottlenecks
Compliance with quality systems
Document control compliance
Maintaining glp/gcp compliance
Managing vendor audits
Data variability reduction

▲Active Projects

Mouse models of kidney fibrosis
In vivo studies with animal models of neuromuscular diseases
Redline review of contracts
In vitro assays for therapeutic proteins
Intellectual property compliance projects
Analytical method development
Fc-fusion molecule characterization
Ex vivo analysis on mouse tissue samples
Preclinical research projects focused on muscle, bone, and stem cell biology
Contract negotiations support

Hiring Activity

Accelerating30 roles · 25 in 30d

Department

Research

16

Healthcare

3

Finance

2

Legal

2

Operations

2

Quality

2

Manufacturing

1

Ops

1

Seniority

Intern

16

Director

6

Mid

4

Manager

1

Senior

1

VP

1

Notable leadership hires: Medical Director

Company intelligence

Find more companies like Keros Therapeutics by tech stack, pain points and active projects

Get started free

About Keros Therapeutics

Keros develops novel therapeutics designed to address disorders linked to dysfunctional TGF-β signaling. The company's active research spans mouse models of kidney fibrosis and neuromuscular disease, in vitro protein assays, and stem cell biology—typical of a preclinical-stage biotech. Current operational focus includes analytical method development, Fc-fusion characterization, and preclinical studies in muscle and bone biology. Headquartered in Lexington, Massachusetts, Keros is a publicly traded company with 51–200 employees, operating across R&D, clinical, quality, manufacturing, and corporate functions.

HeadquartersLexington, Massachusetts

Company Size51–200 employees

Founded2016

Hiring MarketsUnited States

Frequently Asked Questions

What is Keros Therapeutics working on?

Keros runs preclinical research on mouse models of kidney fibrosis and neuromuscular diseases, develops in vitro assays for therapeutic proteins, and characterizes Fc-fusion molecules. Active projects also include analytical method development and IP compliance work.

What tech and tools does Keros use?

Core lab tools include qPCR, GraphPad Prism, SDS-PAGE, and HPLC for analytical work. Administrative stack: DocuSign, Veeva QualityDocs (regulatory/quality), Microsoft Office, SPSS, and Excel. No adopting or replacing moves listed.